• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 3rd March 2020

Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds

OHE has published a white paper discussing the relative merits and shortfalls of current approaches to defining, estimating, and applying cost-effectiveness thresholds in HTA. This will be accompanied by a (forthcoming) research paper exploring bargaining in threshold setting OHE has…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

OHE has published a white paper discussing the relative merits and shortfalls of current approaches to defining, estimating, and applying cost-effectiveness thresholds in HTA.

This will be accompanied by a (forthcoming) research paper exploring bargaining in threshold setting

OHE has published a white paper analysing the relative merits and shortfalls of current approaches to defining, estimating, and applying cost-effectiveness thresholds (CETs) in Health Technology Assessments (HTA).

HTAs guide funding and reimbursement decisions in healthcare, with the objective of getting the most health benefit from the (limited) resources. Many countries conduct HTAs using cost-effectiveness analysis (CEA), which measures the additional cost incurred by a new intervention to gain one additional quality-adjusted life-year (QALY), relative to standard care. This may then be compared against a pre-chosen value – the CET – the maximum expenditure deemed appropriate for this gain. A threshold that is too high or too low will lead to inefficient resource allocation.

The main approaches for setting a CET are a demand-side approach, based on the willingness-to-pay principle and assumption of flexible healthcare budgets, and a supply-side approach based on the opportunity cost principle and assumption of fixed budgets. Applying current CET estimates, based on these approaches, on HTA decision making has been subject to ongoing debate due to limitations of underlying data and assumptions which do not always match reality.

Countries using CETs do so either explicitly – by specifying the threshold in formal HTA guidelines (e.g. the National Institute for Health and Care Excellence (NICE) in the UK) – or implicitly – where a threshold is informally accepted by decision makers (e.g. Canada – before the Patented Medicines Prices Review Board (PMPRB) reforms – and Australia). Although the UK and, more recently, Canada, have endorsed the concept of opportunity cost thresholds, the CET values applied in practice are higher than the empirical estimates based on that concept. The consequences of this discrepancy depend on the extent to which the estimated CETs reflect actual opportunity costs.

As HTA systems review their methods and CETs are used as a tool for price regulation, there is need for debate on how best to identify a threshold to support health system goals, given limited resources, and to meet patients’ needs. In Canada, the PMPRB is establishing a new nationwide system, where the maximum (rebated) price of patented medicines with yearly sales or annual treatment costs exceeding a certain amount will be set using market size and the pharmacoeconomic factors of treatment cost, incremental cost and incremental QALYs, valued using a CET of CAD60,000 per QALY gained.

The use of QALY-based CEAs has also been questioned due to shortcomings in its ability to reflect the full value of health interventions. Today’s HTA methods need to be reviewed to ensure they are fit for purpose for future value assessment of new technologies such as curative therapies or other major innovations that may result in high values for patients and society.

The main recommendations are:

  • Health agencies currently considering the application of an explicit CET should do so in stages (e.g. start with a threshold based on past decisions) to avoid major shocks to the system and improve its predictability. A soft approach should involve introducing the threshold as a range, rather than a single value.
  • Systems already applying an explicit threshold should explore the relationship between supply-side and demand-side estimates, and how the two can converge in the long-run. There is also need to recognise data barriers underlying current supply-side estimates, and to be receptive to new approaches.

One new approach will be presented in a forthcoming OHE research paper where Berdud, Ferraro and Towse (2020) propose a supply and demand model to identify the optimal threshold, based on the framework by Pandey et al. (2018), which has been discussed by the PMPRB Working Group. Novel elements of the model include the incorporation of bargaining and Research & Development (R&D) costs to link pharmaceutical pricing and social surplus (the sum of health gains and industry profits) to optimal CETs.

The model interprets cost-reducing policy tools and competition among medicines still on patent as an increase in bargaining power of the payer. Consequently, the set price leads to an Incremental Cost-Effectiveness Ratio lower than the supply-side CET, and a share of the developers’ profits is captured by the health system. Thus, the maximum acceptable CET can exceed the supply-side threshold value increasing patient access, while net health benefits are still generated.

The model also indicates that, at some CET values, developers do not recover R&D costs. While developers may supply medicines at a loss in the short-term, they may reduce R&D investment in the long-term. To avoid this, the CET should be set at a level that allows for positive returns after R&D costs.

The key conclusion from both the white paper and the research paper is that using a single, rigid CET for price regulation and resource allocation decisions might reduce access to future valuable interventions. The model shows that a flexible approach can maximise patients’ health benefits while providing incentives for continuing intervention improvements. Similarly, the white paper concludes that multiple thresholds reflecting value from different perspectives may be needed. More research is required to understand how new spending is accommodated within the system, and whether society is willing to trade off health gains for other benefits valued by patients and society.  

Citation

Cubi-Molla, P., Errea, M., Zhang, K. and Garau, M., 2020. Are cost-effectiveness thresholds fit for purpose for real-world decision making? OHE Consulting Report. London: Office of Health Economics. Available at: https://www.ohe.org/publications/are-cost-effectiveness-thresholds-fit-purpose-real-world-decision-making

Berdud M., Ferraro J., Towse A. A theory on ICER pricing and optimal level of cost-effectiveness threshold: a bargaining approach. OHE Consulting Report, London: Office of Health Economics. (forthcoming)

 

Related research

Hernandez-Villafuerte, K., Zamora, B., Parkin, D., Devlin, N. and Towse, A., 2019. Exploring variations in the opportunity cost cost-effectiveness threshold by clinical area: Results from a feasibility study in England. OHE Research Paper 18/07. Available at https://www.ohe.org/publications/exploring-variations-opportunity-cost-cost-effectiveness-threshold-clinical-area

Hernandez-Villafuerte, K., Zamora, B. and Towse, A., 2018. Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research. OHE Research Paper 18/07. Available at https://www.ohe.org/publications/issues-surrounding-estimation-opportunity-cost-adopting-new-health-care-technology

Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., and Towse, A (2019). The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK. OHE Research Paper. Available at https://www.ohe.org/publications/case-risperidone-assessing-life-cycle-value-second-generation-antipsychotics-sweden-and

Pandey, H., 2018. Theoretical models of the cost-effectiveness threshold, value assessment, and health care system sustainability. Institute of Health Economics. Available at https://www.ihe.ca/publications/theoretical-models-of-the-cost-effectiveness-threshold-value-assessment-and-health-care-system-sustainability

  • Drug Development/R&D
  • Economics of Innovation
  • Consulting Reports

Related News

  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
  • News
  • July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!